← back to search

Yangliu Xia

National Cancer Institute · US
Area of research
Pharmacology · Oncology
Research interest
Research interests include Pharmacogenetics and Drug Metabolism, Liver Disease Diagnosis and Treatment, Electrochemical sensors and biosensors, and Drug Transport and Resistance Mechanisms.
h-index
20
citations
1,349
works
68
NIH funding
—
primary concept
Chemistry
email
✉ Find email ↗

Recent publications

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis
Hepatology 2022cited by 111position: middledoi
Identification and characterization of human UDP-glucuronosyltransferases responsible for the in-vitro glucuronidation of arctigenin
Journal of Pharmacy and Pharmacology 2015cited by 14position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ping Wang · Nanjing University of Chinese Medicine2 papers (2015–2022)Aijuan Qu · Beijing Obstetrics and Gynecology Hospital1 papers (2022–2022)Weiwei Liu · Shenyang Pharmaceutical University1 papers (2022–2022)Qiong Wang · China Academy of Information and Communications Technology1 papers (2022–2022)Wei He · Boston Children's Hospital1 papers (2015–2015)Changdong Zhao · Hebei University of Technology1 papers (2022–2022)Oksana Gavrilova · National Institute of Diabetes and Digestive and Kidney Diseases1 papers (2022–2022)Daxesh P. Patel · National Cancer Institute1 papers (2022–2022)Ling Yang · Fudan University1 papers (2015–2015)Shoumei Yang · University of Science and Technology of China1 papers (2022–2022)Jie Hou · Nanjing Agricultural University1 papers (2015–2015)Xuan Wu · Hebei Medical University1 papers (2022–2022)Changtao Jiang · Capital Medical University1 papers (2022–2022)Tingting Yan · Research Institute of Wood Industry1 papers (2022–2022)Lulu Sun · Jilin University1 papers (2022–2022)Haiping Hao · Huaqiao University1 papers (2022–2022)Jie Cai · University of Southern California1 papers (2022–2022)Guang‐Bo Ge · Nanjing University of Chinese Medicine1 papers (2015–2015)Yuhong Luo · DMA Health Strategies1 papers (2022–2022)Xiaoting Yu · National Cancer Institute1 papers (2022–2022)